387 related articles for article (PubMed ID: 32974031)
1. Epigenetic based synthetic lethal strategies in human cancers.
Gao A; Guo M
Biomark Res; 2020; 8():44. PubMed ID: 32974031
[TBL] [Abstract][Full Text] [Related]
2. Synthetic lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancer.
Hu Y; Guo M
Cancer Sci; 2020 Sep; 111(9):3111-3121. PubMed ID: 32639661
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in DDR (DNA damage response) inhibitors for cancer therapy.
Cheng B; Pan W; Xing Y; Xiao Y; Chen J; Xu Z
Eur J Med Chem; 2022 Feb; 230():114109. PubMed ID: 35051747
[TBL] [Abstract][Full Text] [Related]
4. The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer.
Gao D; Herman JG; Guo M
Oncotarget; 2016 Jun; 7(24):37331-37346. PubMed ID: 26967246
[TBL] [Abstract][Full Text] [Related]
5. Roles of the PARP Inhibitor in
Inoue T; Sekito S; Kageyama T; Sugino Y; Sasaki T
Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174127
[TBL] [Abstract][Full Text] [Related]
6. Targeting DNA repair pathway in cancer: Mechanisms and clinical application.
Wang M; Chen S; Ao D
MedComm (2020); 2021 Dec; 2(4):654-691. PubMed ID: 34977872
[TBL] [Abstract][Full Text] [Related]
7. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
[TBL] [Abstract][Full Text] [Related]
8. Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.
Takagi M; Yoshida M; Nemoto Y; Tamaichi H; Tsuchida R; Seki M; Uryu K; Nishii R; Miyamoto S; Saito M; Hanada R; Kaneko H; Miyano S; Kataoka K; Yoshida K; Ohira M; Hayashi Y; Nakagawara A; Ogawa S; Mizutani S; Takita J
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059438
[TBL] [Abstract][Full Text] [Related]
9. Alterations of DNA damage repair in cancer: from mechanisms to applications.
Jiang M; Jia K; Wang L; Li W; Chen B; Liu Y; Wang H; Zhao S; He Y; Zhou C
Ann Transl Med; 2020 Dec; 8(24):1685. PubMed ID: 33490197
[TBL] [Abstract][Full Text] [Related]
10. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
[TBL] [Abstract][Full Text] [Related]
11. Synthetic Lethality - Its Current Application and Potential in Oncological Treatment.
Bortlíková L; Müller P; Vojtěšek B; Rak V; Svoboda M
Klin Onkol; 2019; 32(Supplementum 3):19-24. PubMed ID: 31627702
[TBL] [Abstract][Full Text] [Related]
12. The DNA Damaging Revolution: PARP Inhibitors and Beyond.
Yap TA; Plummer R; Azad NS; Helleday T
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():185-195. PubMed ID: 31099635
[TBL] [Abstract][Full Text] [Related]
13. Anti-Tumor Effect of Inhibition of DNA Damage Response Proteins, ATM and ATR, in Endometrial Cancer Cells.
Takeuchi M; Tanikawa M; Nagasaka K; Oda K; Kawata Y; Oki S; Agapiti C; Sone K; Miyagawa Y; Hiraike H; Wada-Hiraike O; Kuramoto H; Ayabe T; Osuga Y; Fujii T
Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31805725
[No Abstract] [Full Text] [Related]
14. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
Criscuolo D; Morra F; Giannella R; Cerrato A; Celetti A
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242618
[TBL] [Abstract][Full Text] [Related]
15. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
[TBL] [Abstract][Full Text] [Related]
16. Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies.
Minchom A; Aversa C; Lopez J
Ther Adv Med Oncol; 2018; 10():1758835918786658. PubMed ID: 30023007
[TBL] [Abstract][Full Text] [Related]
17. Candidate synthetic lethality partners to PARP inhibitors in the treatment of ovarian clear cell cancer.
Kawahara N; Ogawa K; Nagayasu M; Kimura M; Sasaki Y; Kobayashi H
Biomed Rep; 2017 Nov; 7(5):391-399. PubMed ID: 29109859
[TBL] [Abstract][Full Text] [Related]
18. ATM, ATR, CHK1, CHK2 and WEE1 inhibitors in cancer and cancer stem cells.
Ronco C; Martin AR; Demange L; Benhida R
Medchemcomm; 2017 Feb; 8(2):295-319. PubMed ID: 30108746
[TBL] [Abstract][Full Text] [Related]
19. PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer.
Paul I; Savage KI; Blayney JK; Lamers E; Gately K; Kerr K; Sheaff M; Arthur K; Richard DJ; Hamilton PW; James JA; O'Byrne KJ; Harkin DP; Quinn JE; Fennell DA
J Pathol; 2011 Aug; 224(4):564-74. PubMed ID: 21706479
[TBL] [Abstract][Full Text] [Related]
20. FET fusion oncoproteins disrupt physiologic DNA repair networks and induce ATR synthetic lethality in cancer.
Menon S; Breese MR; Lin YP; Allegakoen H; Perati S; Heslin A; Horlbeck MA; Weissman J; Sweet-Cordero EA; Bivona TG; Tulpule A
Res Sq; 2023 May; ():. PubMed ID: 37398210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
